Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
CQO | how to fill the tax form | 16/07/12 | 0 | 541 | |||
|
|||||||
CQO +DBA | Ann: Ceasing to be a substantial holder in CQO by | 01/05/12 | 0 | 636 | |||
|
|||||||
CQO | Ann: Removal from official list close of trading | 01/05/12 | 0 | 659 | |||
|
|||||||
CHC +CQO | Ann: Business Update | 01/05/12 | 0 | 1.1K | |||
|
|||||||
CQO | Ann: Tax Components Payments on Implementation | 30/04/12 | 0 | 611 | |||
|
|||||||
CQO | Ann: Implementation of Proposal | 30/04/12 | 0 | 620 | |||
|
|||||||
CQO | Ann: Change in substantial holding - Additional I | 24/04/12 | 0 | 502 | |||
|
|||||||
CQO | Ann: Distribution Confirmation | 20/04/12 | 1 | 913 | |||
|
See All Discussions